Inclusive of all taxes
Free Express Secure Delivery
Protective climate-sealed dispatch across India within 4 to 24 hours.
Order through WhatsAppFinancial Assistance Available
Manufacturer patient assistance program (PAP) available for Tagrisso 80mg Tablet. Eligible patients can access subsidized treatment schemes.
About this medicine
Tagrisso 80mg Tablet (Osimertinib (80mg))is a prescription oncology medicine. Below is educational product information — follow your doctor's advice for dose and use.
Tagrisso 80mg Tablet is a protein kinase inhibitor used in the treatment of non-small cell lung cancer. It is used in the treatment of adult patients who have certain estimated glomerular filtration rate (EGFR) mutations.This medicine can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.Diarrhea is very common side effect of this medicine, so drink plenty of fluids. But, you must inform your doctor if it does not stop. You must have to inform your doctor if you experience difficulty in breathing along with fever and cough, or severe peeling of the skin. This medicine may reduce the number of blood cells (decrease white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells.Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.
Quick Facts
Generic Name
Osimertinib (80mg)
Dosage Form
Tablet
Prescription Status
Doctor's Rx Required
Uses of Tagrisso 80mg Tablet
Side Effects of Tagrisso 80mg Tablet
Oncology medicines should be administered strictly under medical supervision. Inform your oncologist immediately if you experience adverse symptoms.
Clinical Safety Advice for Tagrisso 80mg Tablet
Follow expert clinical guidelines regarding interactions, precautions, and medical conditions when taking Tagrisso 80mg Tablet.
It is not known whether it is safe to consume alcohol with Tagrisso 80mg Tablet. Please consult your doctor.
Tagrisso 80mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Tagrisso 80mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Tagrisso 80mg Tablet does not usually affect your ability to drive.
Tagrisso 80mg Tablet is safe to use in patients with kidney disease. No dose adjustment of Tagrisso 80mg Tablet is recommended.
Tagrisso 80mg Tablet is safe to use in patients with liver disease. No dose adjustment of Tagrisso 80mg Tablet is recommended.
Storage & Delivery Protocol
Preservation and climate-safe dispatch guidelines for Tagrisso 80mg Tablet across India.
Storage Conditions
Store in the original container at temperatures below 30°C (86°F). Protect from moisture and direct sunlight. Keep out of reach of children and pets. This medication does not require 2°C–8°C refrigeration.
Climate-Sealed Transit
Dispatched in protective, tamper-evident and moisture-sealed packaging.
Rx Verification
Prescription and genuine batch validated prior to dispatch.
Frequently Asked Questions
Clinical Overview: Tagrisso 80mg Tablet
Tagrisso 80mg Tablet contains Osimertinib, a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is specifically designed to selectively target both EGFR-sensitizing mutations (exon 19 deletion and L858R) and the EGFR T790M resistance mutation in non-small cell lung cancer (NSCLC).
How It Works (Mechanism of Action)
Osimertinib binds covalently to specific mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at significantly lower concentrations than wild-type EGFR. By selectively inhibiting EGFR phosphorylation, Osimertinib blocks downstream oncogenic signaling cascades (including the MAPK and PI3K/Akt pathways), arresting tumor proliferation and promoting apoptosis in malignant cells.
Therapeutic & Treatment Context
Tagrisso is indicated as first-line monotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations, as adjuvant therapy following complete tumor resection in Stage IB-IIIA NSCLC, and for patients with metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after previous EGFR-TKI therapy.
Tagrisso Patient Assistance Program (PAP)
Program Benefits & Scheme Structure
• 1+2 Scheme: When an eligible patient purchases 1 strip of Tagrisso 80mg, they receive 2 extra strips provided by AstraZeneca. • Year 1 Savings: If purchased for 9 months under the 1+2 scheme, the last 3 months of therapy are provided at no cost by the manufacturer. • Year 2+ Savings: From the second year onwards, purchasing 6 months of therapy unlocks the next 6 months at no cost. • Applicable to Indian patients without government reimbursement.
Please note: Vyloo Technologies Pvt. Ltd. does not sponsor, manage, or control the PAP program. We offer complimentary administrative support. Eligible patients may avail of the manufacturer's PAP scheme regardless of whether they choose to fulfill their initial prescription through the Vyloo platform.
Important Clinical Information & Precautions
Tagrisso is a prescription-only specialty oncology medication. Treatment should be initiated and supervised by a qualified medical oncologist. Regular cardiac monitoring (LVEF assessments), pulmonary symptom evaluation (monitoring for interstitial lung disease/pneumonitis), and routine hepatic/renal function tests are recommended during treatment.
Storage & Safe Handling Instructions
Store in the original container at temperatures below 30°C (86°F). Protect from moisture and direct sunlight. Keep out of reach of children and pets. This medication does not require 2°C–8°C refrigeration.
Dosage & Administration Guidelines
The standard recommended dose is 80 mg once daily, taken orally with or without food. If swallowing whole tablets is difficult, the tablet may be dispersed in 50 mL of non-carbonated water and swallowed immediately.
Authoritative References & Medical Sources
- FDA Prescribing Information for Tagrisso (Osimertinib)US FDAView Source
- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung CancerNCCNView Source
- Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer (FLAURA Trial)NEJMView Source
Medical information standards
Educational product information for Tagrisso 80mg Tablet. Not a substitute for advice from your treating doctor or healthcare provider.
- Reviewed by
- Nitin Kumar, D.Pharm (UPPC Reg: 63405)Lead Registered Pharmacist · 11 years clinical experience · Drug licence RLF21DL2025001406, RLF20DL2025001420. See our medical review policy.
- Content dates
- Catalogue copy is re-checked under our editorial standards. Pricing and stock update more often at checkout.
- Business address
- Vyloo Technologies Pvt. Ltd.
10251, F/F, Library Road, Nawab Ganj, Delhi G.P.O., Delhi, North Delhi- 110006, Delhi, IndiaGSTIN 07AAKCV0933E1ZF, 09AAKCV0933E1ZB. More on our drug licence page.
Authoritative references
- CDSCO (India) — Central Drugs Standard Control Organisation — Indian drug regulator
- Ministry of Health & Family Welfare — Government of India health ministry
- WHO Essential Medicines — World Health Organization essential medicines lists
- National Health Portal (India) — Government of India National Health Portal
Have questions about your cancer prescription?
Our licensed oncology pharmacists are available to assist with medicine availability, cold-chain handling, and prescription verification.